Is it necessary for screening irregular antibodies of blood donors?

He, Zhong; Chen, Qingkai; ShaoBin, Chen; Wang, Qing; Zou, Jiaoli; Liu, Zeming; Huang, Su-Yuan; Zeng, Zilang; Che, Jialin

doi:10.46701/apjbg.2018012018001

Cited by 1 publication

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, some countries elect not to routinely screen blood donations for red cell antibodies. In mainland China, there is no regulatory requirement to screen blood donations for non-ABO red cell antibodies [2]. A 2018 study estimated that 0.152% of the Chinese donor population had non-ABO antibodies, with most cases among married women.…”

Section: Comparison With Other Countriesmentioning

confidence: 99%

“…A 2018 study estimated that 0.152% of the Chinese donor population had non-ABO antibodies, with most cases among married women. The study concluded that given the homogenized donor population and predominate presence of IgM antibodies, the clinical benefits of routine antibody testing did not outweigh the resultant economic cost [2].…”

Section: Comparison With Other Countriesmentioning

confidence: 99%

“…Red cell antibody screening is a critical step to identifying unexpected non-ABO antibodies in donor plasma. The reactivity of these antibodies can be variable and has the potential to cause haemolytic transfusion reactions (HTRs) or shortened red cell survival when transfused [1,2]. This event can be severe and potentially fatal.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Routine donor red cell antibody screening: Considering the alternate strategy

et al. 2021

View full text Add to dashboard Cite

Background and Objectives Australian Red Cross Lifeblood (Lifeblood) performs red blood cell (RBC) antibody screening on every whole blood donation. An alternate strategy has been proposed whereby an antibody screen is performed on the first donation and only repeated following pregnancy, transfusion or a significant break between donations (>2 years). We assess the blood safety risks associated with removing antibody screening for every whole blood donation. Materials and Methods A retrospective desktop analysis included all whole blood donations collected by Lifeblood between 01 May 2018 and 30 April 2019 to quantify the antibodies that would have been undetected with the alternate strategy. The strategy was further assessed using the Alliance of Blood Operators Risk‐Based Decision‐Making framework. Results One hundred and seventy‐one routine donors had antibodies for the first time, but reported no sensitizing event since their last donation. Forty‐seven of these had antibodies of a clinically significant specificity and titre that have the potential to cause a haemolytic transfusion reaction (HTR). The calculated risk of undetected antibodies being transfused to an incompatible recipient is 1 in 82,200. Conclusion The estimated risk of HTRs with the alternate strategy results in an increased risk. While the alternate strategy is identified as the most cost‐effective option within the Australian setting, this additional residual risk was not deemed to be acceptable. Blood services would need to determine whether the increase in residual risk stemming from implementation of such a strategy is tolerable.

show abstract

Section: Comparison With Other Countriesmentioning

confidence: 99%

Section: Comparison With Other Countriesmentioning

confidence: 99%